Discontinuation of Development for the Additional Indication of Carpal-Tunnel Syndrome, for Limaprost, an Oral Prostaglandin E1 Analogue

Osaka, Japan, January 25, 2013 – Ono Pharmaceutical Co.,
Ltd. (Ono) and Dainippon Sumitomo Pharma Co., Ltd. (DSP) announced
today that the companies had decided to discontinue development of
limaprost alfadex (generic name: hereinafter...

Source: Drugs.com - Pharma News - January 25, 2013 Category: Pharmaceuticals Source Type: news